Background: This systematic review and meta-analysis of Randomized Controlled Trials (RCTs) were
conducted to determine the effects of coenzyme Q10 (CoQ10) supplementation on metabolic profiles of patients
diagnosed with Chronic Kidney Disease (CKD).
Methods: Two independent reviewers systematically searched online databases including PubMed, Cochrane
Library, and Web of Science databases, Scopus, EMBASE until July 2018 to identify eligible clinical trials. The
heterogeneity across included trials was assessed using Cochran’s Q test and I-square (I2) statistic. Cochrane
Collaboration risk of bias tool was applied to evaluate the quality of selected RCTs. Standardized mean difference
(SMD) and 95% Confidence Interval (CI) between two groups of intervention were used to determine pooled
Results: Out of 721 potential papers, 7 RCTs were appropriate to be included in our meta-analysis. The pooled
results revealed that CoQ10 supplementation significantly reduced total-cholesterol (SMD=-0.58; CI, -0.94, -
0.21; P=0.002; I2: 54.9), LDL-cholesterol (SMD=-0.47; 95% CI, -0.78, -0.17; P=0.003; I2:00.0), malondialdehyde
(MDA) (SMD=-3.0; 95% CI, -5.10, -0.90; P=0.005; I2: 95.4) and creatinine levels (SMD=-1.65; 95% CI, -
2.75, -0.54; P=0.003; I2: 95.0) in patients diagnosed with CKD. Triglycerides, HDL-cholesterol, fasting glucose,
insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and C-reactive protein
(CRP) concentrations did not affect following CoQ10 supplementation.
Conclusion: Overall, the current meta-analysis demonstrated that CoQ10 supplementation significantly improved
metabolic profile in patients with CKD by reducing total cholesterol, LDL-cholesterol, MDA and creatinine levels,
yet it did not affect fasting glucose, insulin, HOMA-IR, and CRP concentrations.